Apricus' stock rises on transdermal platform success; Echo gets patents for needle-free tech;

 @DamianFierce: Drugmakers are rethinking drug delivery methods for multiple sclerosis treatments. Report | Follow @DamianFierce

> Drug delivery firm Apricus Bio's stock has gone up nearly 30% over the last month, and that trend is likely to continue thanks to its NexACT delivery platform. News

> Echo Therapeutics ($ECTE) has secured patents for Symphony, its needle-free glucose monitor, and Prelude, the transdermal platform that makes it work. Story

> IntelGenx ($IGXT) got its OTC Markets listing upgraded, from OTCQB to OTCQX, OTC's highest tier. Release

> Fuse Science is touting positive study results for its transdermal delivery platform, eyeing partnerships in pharmaceuticals and consumer products. More

> Another firm has found a way to use chocolate as a platform to boost the efficacy of treatments. Item  

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.